Warfarin and altered intake: the monitoring argument — the long version posts 121–135

Saving this. It is the version I will quote when the question comes round again.

Two people in this thread mean different things by Warfarin and altered intake and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.

The version of Warfarin and altered intake that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.

Narrowing post #123, because the general version has more than one answer.

Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.

The general answer and the answer for your case may diverge here.

Post #123 put the caveat in the right place and I want to underline it.

Practical answer on Warfarin and altered intake, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.

SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.

Anything that also slows gut motility compounds the same mechanism. That is a plausibility argument rather than a documented interaction, and it should be labelled as one.

I would treat the number as indicative rather than as a measurement.

Where I part company with post #127, and it is a narrow parting.

A request rather than an answer: could whoever has the primary source for Warfarin and altered intake post it? I have seen the claim three times this month and each version had lost a qualifier.

This is the first time the answer has come with its own limits attached. Appreciated.

A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.

It is the sort of thing that seems obvious in retrospect and was not at the time.

Post #129 describes the usual case. This is about the unusual one.

Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.

Not a conclusion. A place to stand while looking for one.

Post #131 is the version of this I will quote in future. One addition.

Since Warfarin and altered intake keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

The most useful reply I ever got about Warfarin and altered intake was a request to state my units. It sounds like pedantry and it has saved me twice.